How does it work?
Tepezza addresses the underlying cause of TED rather than merely the symptoms. Cells in the tissue behind the eye have receptors on their surfaces that operate as switches. When a person has TED, the immune system assaults the affected tissue. The reaction generates autoantibodies, which are chemicals that activate the switches.
This process produces Graves' eye disease symptoms, such as enlargement of the muscles, fat, and tissue in the eye socket. Tepezza's purpose is to bind the switch and prevent it from turning on. It does not cure thyroid eye illness, but it helps alleviate certain symptoms such as inflammation, bulging eyes, and double vision.
Serious Alleged Injuries May Include:
- Permanent hearing loss
- Tinnitus
- Partial hearing loss
- Sensorineural hearing loss
- Patulous eustachian tube dysfunction
- Autophony
- Pulsatile Tinnitus
- Superior canal dehiscence syndrome (SCDS)
FDA Safety Warnings:
TEPEZZA is prescribed as an intravenous infusion of 10 mg/kg for the first dosage, followed by an intravenous infusion of 20 mg/kg every three weeks for seven further infusions.
Legal Updates:
Defendants:
Horizon Pharmaceuticals
Allegations:
Hearing loss, tinnitus, and other hearing issues, including worsening sensorineural hearing loss and patulous eustachian tube, plagued the patients who underwent Tepezza injections.
Click here: legal process outsourcing | Infant compromise | Law Related Articles | drugs information yaz
Lawsuit Status:
Many Tepezza cases have been consolidated into a Multidistrict Lawsuit (MDL) in the US District Court for the Northern District of Illinois as of January 2023. Tepezza litigations are still in the early stages, and no jury judgments or settlements have been reached. Cases are still being accepted by attorneys.
Important Verdicts & Settlements
August 2022:
The first Tepezza hearing loss complaint was brought in response to the manufacturer's refusal to disclose known Tepezza hearing loss adverse effects.
January 2023:
A group of plaintiffs petitioned the Judicial Panel on Multidistrict Litigation, requesting that all Tepezza claims be combined into a multidistrict litigation (MDL) for pooled pretrial hearings before a single federal court.
Evidence
Medical Record Review and Claim validation of the Tepezza case should take approximately 1-2 hours in most instances; however, this approximation may vary in cases based on the volume of records.